Introduction
This workshop was planned, organized and conducted by Walter Royal, M.D., visiting neurologist from Johns Hopkins University School of Medicine, Baltimore, Jag H. Khalsa, Ph.D., Center on AIDS and Other Medical Consequences of Drug Abuse (CAMCODA), and Henry Francis, Director, CAMCODA, both within the National Institute on Drug Abuse (NIDA), a part of the National Institutes of Health (NIH). A group of nationally and internationally recognized neuroscientists/neurologists presented/discussed (i) current data on metabolic complications in the CNS of HIV-infected or AIDS patients using drugs of abuse; (ii) in-vitro tests and in-vivo models for the study of interactions-effects on P450 and other metabolic pathways; (iii) pharmacokinetic/pharmacodynamic aspects of drug action; (iv) the problems of design and conducting such studies in clinical populations; and (v) developing new drugs for the treatment of AIDS and drug addiction. Finally, they made recommendations for future research.
Since many investigators presented new and unpublished data, it was agreed that the abstracts could be placed on the NIDA's web site and only a brief executive summary should be published in a professional journal.
Abstracts
HIV AND DRUG ABUSE IN THE EDINBURGH COHORT: RESEARCH CHALLENGES AND OPPORTUNITIES
Jeanne E. Bell, et al., Western General Hospital
NEUROLOGICAL ASPECTS OF SUBSTANCE ABUSE
John C.M. Brust, M.D.
METABOLIC ABNORMALITIES IN HIV INFECTION
Adrian S. Dobs, M.D., M.H.S., The Johns Hopkins University School of Medicine
AIDS AND OPIATES IN A MONKEY MODEL
Robert M. Donahoe, Ph.D., Emory University School of Medicine
HIV-1-ASSOCIATED DEMENTIA: A METABOLIC ENCEPHALOPATHY FUELED BY VIRAL REPLICATION IN MONONUCLEAR PHAGOCYTES
Howard F. Gendelman, University of Nebraska Medical Center
COCAINE USE, NEUROPSYCHOLOGICAL TEST PERFORMANCE, AND MINOR COGNITIVE-MOTOR DISORDER IN HIV-1 SEROPOSITIVE INDIVIDUALS
Karl Goodkin, M.D., Ph.D., et al. University of Miami School of Medicine
THE HPA AXIS IN HIV-1 INFECTION
Mahendra Kumar, Ph.D., University of Miami School of Medicine
SYNAPTIC DYSFUNCTION AND DEGENERATION IN AIDS
M.P. Mattson, et al., University of Kentucky
DOPAMINERGIC AND NON-DOPAMINERGIC INTERACTIONS BETWEEN HIV PROTEINS AND DRUGS OF ABUSE
A. Nath, Booze RM, Hauser K, Maragos W, Cass W, Mactutus C Departments of Neurology, Microbiology and Immunology, Anatomy and Neurobiology, University of Kentucky, Lexington, KY
MICRONUTRIENTS AND NEUROPSYCHOLOGICAL FUNCTION IN HIV/AIDS
Gail Shor-Posner, Ph.D., University of Miami School of Medicine
Participants
John C.M. Brust, M.D.
Professor
Department of Neurology
Columbia University School of Medicine
506 Lenox Ave
New York, NY 10037
e-mail: jcb2@columbia.edu
Jeanne E. Bell, M.D., F.R.C. Path
Senior Lecturer
Neuropathology Laboratory, Dept. of Pathology
Alexander Donald Building
Western General Hospital
Crewe Road
Edinburgh, EH4 2XU, Scotland, UK
e-mail: jeb@serv0.med.ed.ac.uk
Adrian S. Dobs, M.D.
Associate Professor, Endocrinology
Blalock 906B
Johns Hopkins Hospital
Baltimore, MD 21287
e-mail: adobs@jhmi.edu
Robert Donahoe, Ph.D.
Professor
Department of Psychiatry & Behavioral Sciences
1256 Briarcliff Road
Emory West, Room 3095
Atlanta, GA 30306
e-mail: rdonahoe@emory.edu
Henry (Skip) Francis, M.D.
Director
Center on AIDS & Other Medical Consequences of Drug Abuse (CAMCODA)
National Institute on Drug Abuse, NIH
6001 Executive Blvd, room 5198, msc 9593.
Bethesda, MD 20892-9593
Telephone: 301-443-1801; Fax: 301-443-4100
e-mail: hf23n@nih.gov
Howard E. Gendelman, M.D.
David T. Purtilo Professor of Pathology and Microbiology
Director
Center for Neurovirology and Neurodegenerative Disorders
Swanson Hall
45th and Dewey Ave.
985215 Nebraska Medical Center
Omaha, NE 68198-5215
e-mail: hegendel@mail.unmc.edu
Karl Goodkin, M.D., Ph.D.
Professor
Department of Psychiatry and Behavioral Sciences
School of Medicine
University of Miami
Coral Gables, FL 33124
e-mail: kgoodkin@mednet.med.miami.edu
Jag H. Khalsa, Ph.D.
Health Scientist Administrator
Center on AIDS & Other Medical Consequences of Drug Abuse (CAMCODA)
National Institute on Drug Abuse, NIH
6001 Executive Blvd., room 5198, msc 9593
Bethesda, MD 20892-9593
Telephone: 301-443-1801; Fax: 301-443-4100
e-mail: jk98p@nih.gov
Mahendra Kumar, Ph.D.
Professor
Department of Psychiatry and Behavioral Sciences
University of Miami School of Medicine
Coral Gables, FL
e-mail: mkumar@med.miami.edu
Alan L. Leshner, Ph.D.
Director
National Institute on Drug Abuse
6001 Executive Boulevard, room 5274, msc 9581
Bethesda, MD 20892-9555
e-mail: al16m@nih.gov
Mark Mattson, Ph.D.
University of Kentucky
211 Sanders-Brown Center
800 S. Lime 0230
Lexington, KY 40536
e-mail: mmattson@aging.coa.uky.edu
Avindra Nath, M.D.
Associate Professor
Department of Neurology
University of Kentucky Medical Center
KY Clinic (Wing D)-L445
Lexington, KY 40536-0284
e-mail: anath@pop.uky.edu
Walter Royal, III, M.D.
Associate Professor of Neurology
Johns Hopkins University & Visiting Nurologist
Center on AIDS & Other Medical Consequences of Drug Abuse (CAMCODA)
National Institute on Drug Abuse, NIH
6001 Executive Blvd., room 5198, msc 9593
Bethesda, MD 20892-9593
e-mail: wroyal@jhmi.edu
Gail Shor-Posner, Ph.D.
Associate professor
Dept of Psychiatry & Behavioral Sciences
Div Metabolism & Disease Prevention
University of Miami School of Medicine
1400 Northwest 10th Ave.; 10th Floor, (D21)
Miami, FL 33136
e-mail: gshor@mednet.med.miami.edu